Kameleon007
The FDA has granted full approval for AbbVie’s (NYSE:ABBV) drug Elahere for the treatment of ovarian cancer.
AbbVie said the drug was approved to treat folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
Elahere, which was developed by ImmunoGen, was granted accelerated approval by the FDA in November 2022. The full approval is based upon data from a confirmatory Phase 3 study called MIRASOL.
AbbVie acquired ImmunoGen for around $10B. The deal closed in February.